Strategies for managing cytomegalovirus in transplant recipients

被引:29
作者
Razonable, Raymund R. [1 ]
机构
[1] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Div Infect Dis,Dept Internal Med, Rochester, MN 55905 USA
关键词
cytomegalovirus; outcome; preemptive therapy; prophylaxis; transplantation; valganciclovir; GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; GUIDING PREEMPTIVE THERAPY; CMV-HYPERIMMUNE GLOBULIN; HEMATOPOIETIC STEM-CELL; HIGH-RISK; CLINICAL UTILITY; ORAL GANCICLOVIR; INTRAVENOUS GANCICLOVIR; ALLOGRAFT-REJECTION; VALGANCICLOVIR PROPHYLAXIS;
D O I
10.1517/14656566.2010.492395
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.
引用
收藏
页码:1983 / 1997
页数:15
相关论文
共 114 条
  • [1] Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis
    Akalin, E
    Bromberg, JS
    Sehgal, V
    Ames, S
    Murphy, B
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) : 148 - 149
  • [2] Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation
    Arthurs, Supha K.
    Eid, Albert J.
    Pedersen, Rachel A.
    Kremers, Walter K.
    Cosio, Fernando G.
    Patel, Robin
    Razonable, Raymund R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (06) : 840 - 846
  • [3] Delayed-onset primary cytomegalovirus disease after liver transplantation
    Arthurs, Supha K.
    Eid, Albert J.
    Pedersen, Rachel A.
    Dierichising, Ross A.
    Kremers, Walter K.
    Patel, Robin
    Razonable, Raymund R.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (12) : 1703 - 1709
  • [4] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    Asberg, A.
    Humar, A.
    Rollag, H.
    Jardine, A. G.
    Mouas, H.
    Pescovitz, M. D.
    Sgarabotto, D.
    Tuncer, M.
    Noronha, I. L.
    Hartmann, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) : 2106 - 2113
  • [5] Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation
    Baldanti, Fausto
    Lilleri, Daniele
    Gerna, Giuseppe
    [J]. HEMATOLOGICAL ONCOLOGY, 2008, 26 (03) : 123 - 130
  • [6] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS
    BALFOUR, HH
    CHACE, BA
    STAPLETON, JT
    SIMMONS, RL
    FRYD, DS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) : 1381 - 1387
  • [7] Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients
    Boivin, G
    Goyette, N
    Gilbert, C
    Humar, A
    Covington, E
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2005, 7 (3-4) : 166 - 170
  • [8] Boivin G, 2009, ANTIVIR THER, V14, P697
  • [9] CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis
    Bonaros, Nikolaos
    Mayer, Bernd
    Schachner, Thomas
    Laufer, Guenther
    Kocher, Alfred
    [J]. CLINICAL TRANSPLANTATION, 2008, 22 (01) : 89 - 97
  • [10] The R753Q Polymorphism Abrogates Toll-Like Receptor 2 Signaling in Response to Human Cytomegalovirus
    Brown, Robert A.
    Gralewski, Jonathon H.
    Razonable, Raymund R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : E96 - E99